Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer

Journal of Medical Genetics

Volumn 44, Issue 2, 2007, Pages 107-121

  Simard, Jacques ^a   Dumont, Martine ^a   Moisan, Anne Marie ^a   Gaborieau, Valérie ^b   Vézina, Hélène ^c   Durocher, Francine ^a   Chiquette, Jocelyne ^a   Plante, Marie ^a   Avard, Denise ^d   Bessette, Paul ^e   Brousseau, Claire ^a   Dorval, Michel ^a   Godard, Béatrice ^d   Houde, Louis ^c   Joly, Yann ^d   Lajoie, Marie Andrée ^a   Leblanc, Gilles ^a   Lépine, Jean ^f   Lespérance, Bernard ^g   Malouin, Hélène ^a   Parboosingh, Jillian ^h   Pichette, Roxane ^g   Provencher, Louise ^a   Rhéaume, Josée ^a   Sinnett, Daniel ^d   Samson, Carolle ^a   Simard, Jean Claude ^a   Tranchant, Martine ^a   Voyer, Patricia ⁱ   Easton, Douglas ^j   Tavtigian, Sean V ^b   Knoppers, Bartha Maria ^d   Laframboise, Rachel ^a   Bridge, Peter ^h   Goldgar, David ^b,k   Tremblay, Marc ^c   Sinilnikova, Olga ^b,l   Antoniou, Antonis ^m   Dugas, Michel ⁿ   more..

^a LAVAL UNIVERSITY   (Canada)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITÉ DU QUÉBEC À CHICOUTIMI   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f Centre Hospitalier Regional de Rimouski   (Canada)

^g HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^h ALBERTA CHILDREN'S HOSPITAL   (Canada)

ⁱ Clinique des Maladies du Sein   (Canada)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l HOSPICES CIVILS DE LYON   (France)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ Gina Cody School of Engineering and Computer Science   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC RISK; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; THEORETICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; COHORT STUDIES; DNA, NEOPLASM; FAMILY; FEMALE; FRANCE; GENE AMPLIFICATION; HUMANS; MALE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PREVALENCE; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 33847259648     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.044388     Document Type: Article

References (65)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Yoon PW, Scheuner MT, Khoury MJ. Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 2003;24:128-35.
3. Guttmacher AE, Collins FS, Carmona RH. The family history - more important than ever. N Engl J Med 2004;351:2333-6.
4. Khoury MJ, Little J, Burke W. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. New York: Oxford University Press, 2004.
5. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-60.
6. National Institute for Health and Clinical Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (clinical guideline number 14). 2004. http://www.nice.org.uk/pdf/CG014niceguideline.pdf (accessed 25 Nov 2006).
7. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99.
8. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet 2004;41:801-7.
9. Houlston RS, Peto J. Genetics and the common cancers. In: Eeles RA, Easton DF, Ponder BAJ, Eng C, eds. Genetic predisposition to cancer. New York: Oxford University Press, 2004:235-47.
10. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
11. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000;26:411-14.
12. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
13. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
14. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AK, Shizuya H, Eyfjord JE, Cannon-Albright L, Tranchant M, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-linkea kindreds. Nat Genet 1996;12:333-7.
15. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
16. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-36.
17. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Nogues C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R. Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004). Bull Cancer 2004;91:219-37.
18. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-61.
19. Neuhausen SL. Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2000;2:77-81.
20. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
21. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-97.
22. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet 1996;33:814-19.
23. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA, Futreal PA. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-2.
24. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-51.
25. Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, Provencher D, Tonin PN. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004;112:411-19.
26. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
27. Scriver CR. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2001;2:69-101.
28. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA. Population history and its impact on medical genetics in Quebec. Clin Genet 2005;68:287-301.
29. Antoniou AC, Durocher F, Smith P, Simard J, Easton DF. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006;8:R3.
30. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-74.
31. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
32. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-90.
33. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
34. Evans DG, Lalloo F, Wallace A, Rahman N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005;42:e39.
35. Frank TS. Hereditary risk of breast and ovarian carcinoma: the role of the oncologist. Oncologist 1998;3:403-12.
36. Frank TS, Critchfield GC. Hereditary risk of women's cancers. Best Pract Res Clin Obstet Gynaecol 2002;16:703-13.
37. Simard J, Joly Y, Durocher F, Knoppers BM. Les enjeux éthiaues du partage des résultats de recherche: L'expérience d'INHERIT BRCAs. In: Philips-Nootens S, Godard B, Knoppers BM, Régnier MH, eds. La recherche en génétique et en génomique: droits et responsabilités. Montréal: Les Éditions Tnémis, 2005:103-39.
38. Avard D, Bridge P, Bucci LM, Chiquette J, Dorval M, Durocher F, Easton D, Godard B, Goldgar D, Knoppers BM, Laframboise R, Lesperance B, Plante M, Tavtigian SV, Vezina H, Wilson B, Simard J. Partnering in oncogenetic research - the INHERIT BRCAs experience: opportunities and challenges. Fam Cancer 2006;5:3-13.
39. Godard B, Simard J, INHERIT BRCAs. Les enjeux éthiques de l'identification d'une susceptibilité génétique au cancer du sein dans un contexte de recherche clinique intégrée. In: Hervé C, Knoppers BM, Molinari PA, eds. Les pratiques de recherche biomédicale visitées par la bioéthique. Paris: Dalloz, 2003.
40. Moisan AM, Fortin J, Dumont M, Samson C, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Provencher L, Voyer P, Goldgar DE, Bridge P, Simard J. No evidence of BRCA1/2 genomic rearrangements in high risk French-Canadian breast/ovarian cancer families. Genet Test 2006;10:104-15.
41. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
42. Bouchard G. Projet BALSAC-Rapport annuel 2004-2005. Projet BALSAC, Université du Québec à Chicoutimi, 2005. www.uqac.ca/balsac (accessed 25 Nov 2006).
43. Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, Chiquette J, Plante M, Laframboise R, Lepine J, Nevanlinna H, Stoppa-Lyonnet D, Goldgar D, Bridge P, Simard J. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 2005;117:119-32.
44. Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev 1950;78:1-3.
45. Tremblay M, Vezina H. New estimates of intergenerational time intervals for the calculation of age and origins of mutations. Am J Hum Genet 2000;66:651-8.
46. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
47. Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
48. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002;6:119-21.
49. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 2004;41:492-507.
50. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.
51. Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 2005;65:10096-103.
52. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295-305.
53. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005;65:417-26.
54. Parkin DM, Wjelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents, Vol VIII. Lyon, France: International Agency for Research on Cancer, WHO Press, 2002.
55. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-19.
56. Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001;37:2082-90.
57. Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubinski J. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004;110:683-6
58. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, Neuhausen S. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005;14:1666-71.
59. Bouchard G, Charbonneau H, Desjardins B, Heyer E, Tremblay M. Mobilité géographique et stratification du pool génétique canadien-français sous le régime français. In: Landry Y, Dickinson J, Pasleau S, Desama C, eds. Les chemins de la migration en Belgique et au Québec du XVIIe au XXe siècle. Louvain-La-Neuve: Éditions Académia, 1995:51-9.
60. Gagnon A, Heyer E. Fragmentation of the Quebec population genetic pool (Canada): evidence from the genetic contribution of founders per region in the 17th and 18th centuries. Am J Phys Anthropol 2001;114:30-41.
61. Vézina H, Tremblay M, Houde L. Mesures de l'apparentement biologique au Saguenay-Lac-St-Jean (Québec, Canada) à partir de reconstitutions généalogiques. Ann Démogr Hist 2004;2:67-84.
62. Gerdes AM, Cruger DG, Thomassen M, Kruse TA. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet 2006;69:171-8.
63. Cruger DG, Kruse TA, Gerdes AM. Indirect BRCA1/2 testing. A useful approach in hereditary breast and ovarian cancer families without a living affected relative. Clin Genet 2005;68:228-33.
64. Tranchemontagne J, Boothroyd L, Blancquaert I. Contribution of BRCA1/2 mutation testing to risk assessment for susceptibility to breast and ovarian cancer. Agence D'évaluation des Technologies et Modes d'Interventions en Santé (AETMIS). http://www.aetmis.gouv.qc.ca/site/ index.php?fr_ publications_2006 (accessed 25 Nov 2000).
65. Ontario Predictive Cancer Genetics Steering Committee. Criteria for genetic testing for Brca1 and Brca2 in the province of Ontario (OPCGSC) 2001. http://www.oma.org/pcomm/omr/nov/01genetics.htm (accessed 25 Nov 2006).